December 21, 2016 / 12:14 PM / 8 months ago

BRIEF-Bristol-Myers, Calithera Biosciences collaborate to test opdivo along with CB-839

Dec 21 (Reuters) - Bristol-Myers Squibb Co

* Bristol-Myers Squibb and Calithera Biosciences announce clinical collaboration to evaluate opdivo (nivolumab) in combination with CB-839 in clear cell renal cell carcinoma

* Bristol-Myers Squibb Co says study to evaluate potential of CB-839 plus opdivo to target immune-suppressive cells in tumor microenvironment Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below